Literature DB >> 18724538

Visual analogue scales and assessment of quality of life in cancer.

Katherine Hauser1, Declan Walsh.   

Abstract

Assessment of quality of life (QOL) in cancer clinical trials is important when comparing treatments, especially when prolonged survival is not expected. QOL scores may reflect physical or psychosocial functioning or distress. The choice of QOL instrument depends upon the definition, research hypothesis, cancer population, depth and sensitivity of information required, and frequency of measurement. A visual analogue scale (VAS) is commonly used to rate various subjective experiences. Potential advantages of these scales include their wide score range and high sensitivity; disadvantages include lower completion rates than other rating scales. Single-item VASs are validated for cancer QOL, reliable, and responsive to change. These scales may best represent an individual's global QOL without the constraints of predetermined domains. Single items are useful for frequent measurements in palliative or advanced populations and when information about domains is less important. Multi-item VAS QOL instruments vary in length and domains; they are useful in clinical trials enrolling patients with good performance status, but some are long and disease-specific.

Entities:  

Mesh:

Year:  2008        PMID: 18724538

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  13 in total

1.  Treatment of residual pockets with photodynamic therapy, diode laser, or deep scaling. A randomized, split-mouth controlled clinical trial.

Authors:  Isabelle Cappuyns; Norbert Cionca; Philipp Wick; Catherine Giannopoulou; Andrea Mombelli
Journal:  Lasers Med Sci       Date:  2011-11-22       Impact factor: 3.161

2.  Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).

Authors:  Deirdre R Pachman; Rui Qin; Drew Seisler; Ellen M Lavoie Smith; Suneetha Kaggal; Paul Novotny; Kathryn J Ruddy; Jacqueline M Lafky; Lauren E Ta; Andreas S Beutler; Nina D Wagner-Johnston; Nathan P Staff; Axel Grothey; Patrick M Dougherty; Guido Cavaletti; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2016-08-18       Impact factor: 3.603

Review 3.  Identifying and classifying quality-of-life tools for assessing pressure ulcers after spinal cord injury.

Authors:  Sander L Hitzig; Christina Balioussis; Ethne Nussbaum; Colleen F McGillivray; B Catharine Craven; Luc Noreau
Journal:  J Spinal Cord Med       Date:  2013-05-22       Impact factor: 1.985

4.  Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

Authors:  Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

5.  The ChQoL questionnaire: an Italian translation with preliminary psychometric results for female oncological patients.

Authors:  Giovanni Aschero; Flavio Fenoglio; Maria Giuseppina Vidili; Andrea Wussler
Journal:  Health Qual Life Outcomes       Date:  2010-09-25       Impact factor: 3.186

6.  Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy.

Authors:  Timothy J Judson; Antonia V Bennett; Lauren J Rogak; Laura Sit; Allison Barz; Mark G Kris; Clifford A Hudis; Howard I Scher; Paul Sabattini; Deborah Schrag; Ethan Basch
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

7.  Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy.

Authors:  Deirdre R Pachman; Breanna L Weisbrod; Drew K Seisler; Debra L Barton; Kelliann C Fee-Schroeder; Thomas J Smith; Daniel H Lachance; Heshan Liu; Randy A Shelerud; Andrea L Cheville; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2014-09-24       Impact factor: 3.603

8.  Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity.

Authors:  F Kamin; P S Rommer; M Abu-Mugheisib; W Koehler; F Hoffmann; A Winkelmann; R Benecke; U K Zettl
Journal:  Spinal Cord       Date:  2014-09-16       Impact factor: 2.772

9.  Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage.

Authors:  L E Carlson; A Waller; S L Groff; L Zhong; B D Bultz
Journal:  Br J Cancer       Date:  2012-07-24       Impact factor: 7.640

10.  Changes in carnitine levels through induction chemotherapy in head and neck cancer patients as a potential cause of therapy-related malaise.

Authors:  Tatsuya Ito; Kiyoaki Tsukahara; Hiroki Sato; Akira Shimizu; Isaku Okamoto
Journal:  BMC Cancer       Date:  2021-06-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.